These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36220613)

  • 1. Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose.
    Rose E; Magliulo D; Kyttaris VC
    Clin Immunol; 2022 Dec; 245():109144. PubMed ID: 36220613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
    Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
    Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
    Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
    Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
    Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.
    Avouac J; Miceli-Richard C; Combier A; Steelandt A; Fogel O; Mariaggi AA; Meritet JF; Rozenberg F; Molto A; Allanore Y
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI163-SI168. PubMed ID: 34726701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
    Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
    Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
    Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L
    J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
    Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
    Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
    Magliulo D; Wade SD; Kyttaris VC
    Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
    Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
    Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.
    Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
    Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.
    Troldborg A; Thomsen MK; Bartels LE; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Mikkelsen S; Erikstrup C; Hauge EM; Ammitzbøll C
    J Rheumatol; 2022 Jun; 49(6):644-649. PubMed ID: 35232803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
    Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
    Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab.
    Schultz K; Jannat-Khah D; Spiera R
    J Rheumatol; 2023 Mar; 50(3):420-425. PubMed ID: 36521910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
    Bitoun S; Henry J; Desjardins D; Vauloup-Fellous C; Dib N; Belkhir R; Mouna L; Joly C; Bitu M; Ly B; Pascaud J; Seror R; Roque Afonso AM; Le Grand R; Mariette X
    Arthritis Rheumatol; 2022 Jun; 74(6):927-933. PubMed ID: 34962357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour.
    Ammitzbøll C; Thomsen MK; Andersen JB; Bartels LE; Hermansen MF; Johannsen AD; Mistegaard CE; Mikkelsen S; Vils SR; Erikstrup C; Hauge EM; Troldborg A
    Mod Rheumatol; 2023 Jul; 33(4):777-785. PubMed ID: 35860843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
    Madelon N; Lauper K; Breville G; Sabater Royo I; Goldstein R; Andrey DO; Grifoni A; Sette A; Kaiser L; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
    Clin Infect Dis; 2022 Aug; 75(1):e1037-e1045. PubMed ID: 34791081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
    Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
    Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab.
    Jinich S; Schultz K; Jannat-Khah D; Spiera R
    Arthritis Rheumatol; 2022 May; 74(5):776-782. PubMed ID: 34908241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.